BCRX vs VIR: stock comparison and AI forecast
Biocryst Pharmaceuticals Inc (BCRX) and Vir Biotechnology, Inc. (VIR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BCRX Biocryst Pharmaceuticals Inc
- Market Cap
- $1.95B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
VIR Vir Biotechnology, Inc.
- Price
- $11.02 +7.1% · 6M
- Market Cap
- $1.86B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BCRX and VIR have similar market capitalizations ($1.95B and $1.86B).
- VIR turns -30.5% of its revenue into net income, against -37.4% for BCRX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BCRX | VIR |
|---|---|---|
| Market Cap | $1.95B | $1.86B |
| P/B Ratio | – | 2.08x |
| EPS | $-1.30 | $-1.76 |
| Book Value/Share | – | $5.30 |
| Revenue/Share | $3.76 | – |
| FCF/Share | $1.43 | $-0.84 |
Profitability & Margins
| Metric | BCRX | VIR |
|---|---|---|
| ROE | – | -20.6% |
| ROA | -60.8% | -16.6% |
| ROIC | -73.2% | -20.5% |
| Gross Margin | 97.9% | 50.7% |
| Operating Margin | -30.1% | -34.9% |
| Net Margin | -37.4% | -30.5% |
| EBT Margin | -36.9% | -30.5% |
| Tax Rate | -1.4% | -0.0% |
Financial Health
| Metric | BCRX | VIR |
|---|---|---|
| Current Ratio | 2.71x | 6.30x |
| Quick Ratio | 2.64x | – |
| D/E Ratio | – | 0.24x |
| Financial Leverage | – | 1.24x |
| Interest Coverage | 6.3x | – |
| Working Capital | $335M | $428M |
Cash Flow
| Metric | BCRX | VIR |
|---|---|---|
| Operating Cash Flow | $367M | -$141M |
| Free Cash Flow | $366M | -$142M |
| Capital Spending | -$2M | -$800K |
| OCF Growth YoY | 632.1% | – |
| FCF Growth YoY | 658.3% | – |
| FCF/Sales | 38.0% | – |
| CapEx/Sales | 0.2% | – |
Operational Efficiency
| Metric | BCRX | VIR |
|---|---|---|
| Asset Turnover | 1.63x | – |
| Receivables Turnover | 7.9x | – |
| Inventory Turnover | 1.5x | – |
| Fixed Assets Turnover | 578.5x | – |
| Days Sales Outstanding | 46 days | – |
| Days Inventory | 247 days | – |
| Payables Period | 262 days | 158972 days |
| Cash Conversion Cycle | 31 days | – |
Income Statement
| Metric | BCRX | VIR |
|---|---|---|
| Total Revenue | $962M | – |
| Operating Income | -$289M | -$211M |
| Net Income | -$360M | -$185M |
| R&D Expense | $211M | $413M |
| SG&A Expense | $321M | $102M |
| Cost of Goods Sold | $20M | $30K |
Dividend & Shareholder Information
| Metric | BCRX | VIR |
|---|---|---|
| Shares Outstanding | 256M | 169M |
BCRX vs VIR: stock comparison and AI forecast
Which is bigger, BCRX or VIR?
BCRX and VIR have similar market capitalizations ($1.95B and $1.86B).
Which one does Intratio's AI model rank higher, BCRX or VIR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.